企業を読み込み中
ONCBeone Medicines Ltd.$47.6BA+Just reported
From Editas Medicine's results release of 2026年11月9日; its quarterly report has since been filed.
Actual
$10.4M
+37% y/y
-13% q/q
Guided
—
No guide given
Actual
-$0.15
Guided
—
No guide given
Actual
-$24.3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →売上構成比はFY2025の推計であり、提出された報告書の数字ではありません。
EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.
Editas develops medicines that change deoxyribonucleic acid (DNA) to treat disease. Its CRISPR (clustered regularly interspaced short palindromic repeats) technology uses a guide molecule to direct an enzyme to a chosen DNA location. Its lead medicine, EDIT-401, is being prepared for early human testing to lower low-density lipoprotein (LDL) cholesterol; the company also licenses its technology and works with drug companies on research programs.
Editas Medicine, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$2.17+1.6%11月13日 終値
2026年9月30日までの数値（2026年11月9日提出の10-Qより）
Editas Medicine licenses gene-editing technology to drug companies and develops experimental medicines for people with serious diseases.
Grade B-
株価の下の帯は各日付時点の評価で、その時点までに公開された書類だけで算出しています。
Editas Medicine, Inc. の評価履歴 32 四半期のうち 2 四半期を表示しています。 残る 30 四半期は 2019年3月 まで遡ります。
